137.76MMarket Cap-843P/E (TTM)
21.2840High17.5200Low167.10KVolume17.7300Open17.4500Pre Close3.33MTurnover4.75%Turnover RatioLossP/E (Static)7.05MShares24.400052wk High1.19P/B68.80MFloat Cap10.000052wk Low--Dividend TTM3.52MShs Float382.6000Historical High--Div YieldTTM21.57%Amplitude8.0000Historical Low19.9070Avg Price1Lot Size
Cidara Therapeutics Stock Forum
Cash available will sustain the operations for 24 months (exclude 105mil private placement). Upcoming catalyst September 2025.
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenzau
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first sub...
Dow Jones· 1 min ago
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
No comment yet